These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11791689)

  • 61. The relative bioavailability of salbutamol to the lung using urinary excretion following inhalation from a novel dry powder inhaler: the effect of inhalation rate and formulation.
    Chege JK; Chrystyn H
    Respir Med; 2000 Jan; 94(1):51-6. PubMed ID: 10714479
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler.
    Kemp JP; Hill MR; Vaughan LM; Meltzer EO; Welch MJ; Ostrom NK
    Ann Allergy Asthma Immunol; 1997 Oct; 79(4):322-6. PubMed ID: 9357377
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
    Munzel U; Marschall K; Fyrnys B; Wedel M
    Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler.
    Pickering H; Pitcairn GR; Hirst PH; Bacon PR; Newman SP; Affrime MB; Marino M
    Clin Ther; 2000 Dec; 22(12):1483-93. PubMed ID: 11192139
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler.
    Chavan V; Dalby R
    AAPS PharmSci; 2002; 4(2):E6. PubMed ID: 12102616
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates.
    DeLong M; Wright J; Dawson M; Meyer T; Sommerer K; Dunbar C
    J Aerosol Med; 2005; 18(4):452-9. PubMed ID: 16379620
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalation powder.
    Hagiwara M; Delea TE; Stanford RH
    J Asthma; 2013 Apr; 50(3):287-95. PubMed ID: 23305687
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mometasone furoate dry powder inhaler for the treatment of asthma.
    Fausnight TB; Craig TJ
    Expert Opin Pharmacother; 2011 Dec; 12(17):2707-12. PubMed ID: 22049912
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Powder inhalation systems].
    Kohlhäufl M; Haidl P; Voshaar T; Häussinger K; Köhler D
    Dtsch Med Wochenschr; 2004 Sep; 129(39):2048-52. PubMed ID: 15386209
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mometason furoate levels.
    Lipworth BJ
    Chest; 2001 Sep; 120(3):1034-5. PubMed ID: 11555548
    [No Abstract]   [Full Text] [Related]  

  • 72. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates.
    Chrystyn H
    Respir Med; 2003 Feb; 97(2):181-7. PubMed ID: 12587970
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clickhaler dry powder inhaler: focussed in vitro proof of principle evaluation of a new chemical entity for asthma.
    Thibert R; Parry-Billings M; Shott M
    Int J Pharm; 2002 Jun; 239(1-2):149-56. PubMed ID: 12052700
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Delivery of salbutamol and of budesonide from a novel multi-dose inhaler Airmax.
    Zeng XM; O'Leary D; Phelan M; Jones S; Colledge J
    Respir Med; 2002 Jun; 96(6):404-11. PubMed ID: 12117039
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evolution of dry powder inhaler design, formulation, and performance.
    Newman SP; Busse WW
    Respir Med; 2002 May; 96(5):293-304. PubMed ID: 12113378
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Delivery of formoterol from a novel multi-dose inhaler Airmax.
    Zeng XM; Jones S; O'Leary D; Phelan M; Colledge J
    Respir Med; 2002 Jun; 96(6):397-403. PubMed ID: 12117038
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size.
    Coates MS; Chan HK; Fletcher DF; Raper JA
    J Pharm Sci; 2006 Jun; 95(6):1382-92. PubMed ID: 16625656
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone.
    Hoffmann K; Auer T; Stücker M; Hoffmann A; Altmeyer P
    J Eur Acad Dermatol Venereol; 1998 Mar; 10(2):137-42. PubMed ID: 9553910
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Systematic Evaluation of the Effect of Formulation Variables on In Vitro Performance of Mometasone Furoate Suspension-Metered Dose Inhalers.
    Bachhav SS; Sheth P; Sandell D; Svensson M; Bhagwat S; Conti DS; Oguntimein O; Dhapare S; Saluja B; Winner L; Bulitta JB; Hochhaus G
    AAPS J; 2021 Dec; 24(1):9. PubMed ID: 34874508
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of rise in simulated inspiratory flow rate and carrier particle size on powder emptying from dry powder inhalers.
    Chavan V; Dalby R
    AAPS PharmSci; 2000; 2(2):E10. PubMed ID: 11741226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.